MIST Milestone Pharmaceuticals

Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024

Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024

MONTREAL and CHARLOTTE, N.C., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced an upcoming data presentation on etripamil at the annual meeting of the European Society of Cardiology, in London, United Kingdom on August 30, 2024. Professor John Camm will present patient reported outcomes data from the NODE-303 Phase 3 trial of etripamil in paroxysmal supraventricular tachycardia (PSVT) in a moderated poster presentation. The poster presentation will be available following the embargo at: .

“We look forward to Professor Camm’s upcoming presentation at the ESC Congress 2024 on this important topic of PSVT and the self-administration of investigational etripamil nasal spray in a medically unsupervised setting,” said David Bharucha, MD, PhD, FACC, Chief Medical Officer, Milestone Pharmaceuticals. “These patient-reported outcomes data, that will be presented, provide insights about patient experience, satisfaction, and disease management.”

ESC Presentation Details:

Moderated Poster Presentation Title:

Quality of Life Measures with Etripamil Self-Administration for Acute Episodes of Paroxysmal Supraventricular Tachycardia in a Medically Unsupervised Setting: Patient-Reported Outcomes from NODE-303

Presenter:

John Camm, MD, Professor of Clinical Cardiology, St. George's University of London, United Kingdom

Date and time:

Friday, August 30, 2024, 13:00 – 13:50 BST

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.

Contact:

Kim Fox, Vice President, Communications,

Investor Relations

Chris Calabrese,

Kevin Gardner,



EN
26/08/2024

Underlying

MISTMilestone Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Milestone Pharmaceuticals

 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel a...

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer New appointment strengthens executive leadership commensurate with launch of CARDAMYST™ (etripamil) nasal spray MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as , the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular ...

February 10, 2026 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listi...

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MONTREAL and CHARLOTTE, N.C., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 419,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of two new employees....

February 3, 2026 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (e...

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional launch in mid-FebruaryExpected $25 copay cap for eligible commercially insured patientsLaunch supported by comprehensive patient assistance program offering benefits verification and reimbursement support MONTREAL and CHARLOTTE, N.C., Jan. 26, 2026 (GLOB...

January 26, 2026 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorizat...

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency  European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the healthcare setting MONTREAL and CHARLOTTE, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medici...

January 6, 2026 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and...

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables development of AFib-RVR under sNDA pathwayMilestone well-capitalized to launch and commercialize CARDAMYST with existing capital and royalty financingConference call and webcast December 15, 8:00 a.m. ET MONTREAL and CHARLOTT...

December 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch